The University of Southampton
University of Southampton Institutional Repository

A double-blind, placebo-controlled study of vortioxetine in the treatment of binge-eating disorder

A double-blind, placebo-controlled study of vortioxetine in the treatment of binge-eating disorder
A double-blind, placebo-controlled study of vortioxetine in the treatment of binge-eating disorder

Background: Binge-eating disorder (BED) is associated with impaired quality of life and has a number of untoward public health associations. There are few established pharmacological treatments for BED, and available options are not suitable for all individuals. Vortioxetine is a recently developed pharmacological agent with effects on the serotonergic but also other neurochemical systems, which has yet to be evaluated in this context. Method: Eighty adults with BED were recruited for a double-blind, placebo-controlled study. Participants received 12-week treatment with vortioxetine (10 mg/day for 1 week, then increasing to 20 mg/day) or placebo in a parallel design. The primary efficacy outcome measures were binge-eating frequency and weight. Safety data were collected. Effects of active versus placebo treatment were characterized using linear repeated measures models. Results: Both vortioxetine and placebo treatment were associated with significant reductions in binge-eating frequency. Vortioxetine did not differentiate significantly from placebo on any efficacy measure. Frequency of adverse events did not differ between groups. Discussion: Vortioxetine was not more effective than placebo in the treatment of BED. The ability to detect pharmacological treatment benefit may have been hindered by the relatively high placebo response and drop out. Future work should seek to better understand and predict placebo response in BED, with a view to more targeted treatment interventions and, potentially, sample enrichment.

antidepressant, binge eating, obesity, pharmacology, treatment
0276-3478
786-794
Grant, Jon E.
07372bd5-8a0d-42b4-b41b-e376c652acf3
Valle, Stephanie
fdb6f4ca-a7e1-4e3d-bbf5-4dd380570aa5
Cavic, Elizabeth
0811dc24-44e4-4758-b4db-e83d39bc5a79
Redden, Sarah A.
f2109178-7158-46c7-971f-4a602a3adf59
Chamberlain, Samuel R.
8a0e09e6-f51f-4039-9287-88debe8d8b6f
Grant, Jon E.
07372bd5-8a0d-42b4-b41b-e376c652acf3
Valle, Stephanie
fdb6f4ca-a7e1-4e3d-bbf5-4dd380570aa5
Cavic, Elizabeth
0811dc24-44e4-4758-b4db-e83d39bc5a79
Redden, Sarah A.
f2109178-7158-46c7-971f-4a602a3adf59
Chamberlain, Samuel R.
8a0e09e6-f51f-4039-9287-88debe8d8b6f

Grant, Jon E., Valle, Stephanie, Cavic, Elizabeth, Redden, Sarah A. and Chamberlain, Samuel R. (2019) A double-blind, placebo-controlled study of vortioxetine in the treatment of binge-eating disorder. International Journal of Eating Disorders, 52 (7), 786-794. (doi:10.1002/eat.23078).

Record type: Article

Abstract

Background: Binge-eating disorder (BED) is associated with impaired quality of life and has a number of untoward public health associations. There are few established pharmacological treatments for BED, and available options are not suitable for all individuals. Vortioxetine is a recently developed pharmacological agent with effects on the serotonergic but also other neurochemical systems, which has yet to be evaluated in this context. Method: Eighty adults with BED were recruited for a double-blind, placebo-controlled study. Participants received 12-week treatment with vortioxetine (10 mg/day for 1 week, then increasing to 20 mg/day) or placebo in a parallel design. The primary efficacy outcome measures were binge-eating frequency and weight. Safety data were collected. Effects of active versus placebo treatment were characterized using linear repeated measures models. Results: Both vortioxetine and placebo treatment were associated with significant reductions in binge-eating frequency. Vortioxetine did not differentiate significantly from placebo on any efficacy measure. Frequency of adverse events did not differ between groups. Discussion: Vortioxetine was not more effective than placebo in the treatment of BED. The ability to detect pharmacological treatment benefit may have been hindered by the relatively high placebo response and drop out. Future work should seek to better understand and predict placebo response in BED, with a view to more targeted treatment interventions and, potentially, sample enrichment.

This record has no associated files available for download.

More information

Published date: July 2019
Keywords: antidepressant, binge eating, obesity, pharmacology, treatment

Identifiers

Local EPrints ID: 493323
URI: http://eprints.soton.ac.uk/id/eprint/493323
ISSN: 0276-3478
PURE UUID: 247f7063-1b98-46ce-9199-0b201053d417
ORCID for Samuel R. Chamberlain: ORCID iD orcid.org/0000-0001-7014-8121

Catalogue record

Date deposited: 29 Aug 2024 16:49
Last modified: 30 Aug 2024 02:00

Export record

Altmetrics

Contributors

Author: Jon E. Grant
Author: Stephanie Valle
Author: Elizabeth Cavic
Author: Sarah A. Redden
Author: Samuel R. Chamberlain ORCID iD

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×